Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting...
February 24 2020 - 8:00AM
Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology
company developing antolimab (AK002) for the treatment of
eosinophil and mast cell related diseases, today announced that the
Company will present clinical and preclinical results in a number
of diseases where mast cells and/or eosinophils have been shown to
play a role in disease pathology. The presentations will take place
at the 2020 American Academy of Allergy Asthma & Immunology
(AAAAI) Annual Meeting being held in Philadelphia, Pa. from March
13 to 16, 2020.
Oral Presentations:
Title (Abstract): |
AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and
Improves Dysphagia Symptoms in Patients with Eosinophilic
Esophagitis (#539) |
Presenter: |
Ikuo Hirano, MD |
Session/Time: |
Advances in Eosinophilic
Esophagitis/March 15, 2:00-3:15 pm |
Title (Abstract): |
Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody,
in Treatment-Refractory Chronic Urticaria (#779) |
Presenter: |
Sabine Altrichter, MD |
Session/Time: |
Atopic Dermatitis with a Side of
Urticaria/March 16, 2:00-3:15 pm |
Featured Poster Presentations:
Title (Abstract): |
AK002, an Anti-Siglec-8 Antibody, Suppresses Acute IL-33-induced
Neutrophil Infiltration and Attenuates Tissue Damage in a Chronic
Experimental COPD Model Through Mast Cell Inhibition (#568) |
Presenter: |
Julia Schanin, PhD |
Session/Time: |
New Insights in Asthma Genomics
and Cell Signaling/March 15, 4:45-6:15 pm |
Title (Abstract): |
Phase 1b Study of AK002, an
Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic
Conjunctivitis (KRONOS Study) (#593) |
Presenter: |
Terry Levine, MD |
Session/Time: |
Headlines in Immunotherapy,
Rhinitis, Sinusitis and Ocular Disease/March 15, 4:45-6:15 pm |
Poster Presentations:
Title (Abstract): |
Atopic Dermatitis Skin Biopsies
Have High Numbers of Activated Mast Cells that are Inhibited by
AK002 after Stimulation Ex Vivo (#637) |
Presenter: |
Amol P. Kamboj, MD |
Session/Time: |
Atopic Dermatitis/March 16,
9:45-10:45 am |
|
|
|
|
Title (Abstract): |
EoE Biopsies have Elevated and
Activated Mast Cells that Produce Cytokines and Chemokines that
Drive Disease Pathogenesis (#129) |
Presenter: |
Bradford A. Youngblood, PhD |
Session/Time: |
Pathogenesis and Treatment of
Eosinophilic Esophagitis/March 14, 9:45-10:45 am |
Title (Abstract): |
A
Longitudinal, Population-Based Study of the Difficult Journey to
Diagnosis Endured by Patients with Eosinophilic Gastritis and
Eosinophilic Gastroenteritis (#121) |
Presenter: |
Mirna Chehade, MD MPH |
Session/Time: |
Diagnosis of Eosinophilic
Esophagitis/March 14, 9:45-10:45 am |
Following the presentations, the posters will be available on
the Allakos website.
About Allakos Allakos is a clinical stage
biotechnology company developing antibodies that target
immunomodulatory receptors present on immune effector cells
involved in allergic, inflammatory, and proliferative diseases. The
Company’s lead antibody, antolimab (AK002), targets Siglec-8, an
inhibitory receptor selectively expressed on human mast cells and
eosinophils. Antolimab (AK002) has been shown to inhibit mast cells
and deplete eosinophils. Inappropriately activated eosinophils and
mast cells have been identified as key drivers in a number of
severe diseases affecting the gastrointestinal tract, eyes, skin,
lungs and other organs. Antolimab (AK002) has been tested in five
clinical studies. In these studies, antolimab (AK002) eliminated
blood eosinophils and improved disease symptoms in patients with
eosinophilic gastritis and/or eosinophilic gastroenteritis,
eosinophilic esophagitis, severe allergic conjunctivitis, chronic
urticaria, and indolent systemic mastocytosis. For more
information, please visit the Company's website at
www.allakos.com
Source: Allakos Inc.
Investor Contact:
Adam Tomasi, President & COO
investors@allakos.com
Media Contact:
Denise Powell
denise@redhousecomms.com
Allakos (NASDAQ:ALLK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allakos (NASDAQ:ALLK)
Historical Stock Chart
From Apr 2023 to Apr 2024